The Dual Agonist Arms Race
Tirzepatide established the superiority of dual-agonists (GIP/GLP-1). The future, currently unfolding in Phase 2 and 3 clinical trials, belongs to compounds exploring different receptor combinations, primarily focusing on Glucagon. Survodutide (Boehringer Ingelheim/Zealand Pharma) and Mazdutide (Innovent Biologics/Eli Lilly) are the leading candidates.
These compounds target the GLP-1 and Glucagon receptors, specifically aiming to enhance energy expenditure drastically, pushing beyond mere appetite suppression.
Survodutide: Liver Fat Eradication
Survodutide is a dual GLP-1/Glucagon receptor agonist. Its clinical trial design heavily targets MASH (metabolic dysfunction-associated steatohepatitis) along with obesity. In Phase 2 trials, it showed up to 83% of adults with MASH saw significant improvement in their liver disease stages alongside nearly 19% body weight loss.
The glucagon component directly oxidizes intrahepatic fat (fat within the liver), essentially reversing fatty liver disease mechanically while the GLP-1 component controls systemic energy balance.
Mazdutide: The Chinese Frontrunner
Mazdutide (IBI362) is a similar dual GLP-1/Glucagon agonist developed structurally from the mammalian oxyntomodulin sequence. In its Phase 3 GLORY-1 trial in Chinese adults with obesity, the 9mg dose resulted in an 18.6% weight reduction at 48 weeks.
Furthermore, it dramatically improved cardio-metabolic markers, reducing blood pressure, triglycerides, and serum uric acid. It proves that the Glucagon interaction is highly synergistic with GLP-1 rather than antagonistic as previously feared.
Timeline to Market
We are witnessing the rapid obsolescence of older single-agonist GLP-1s (like Liraglutide and standard Semaglutide). Mazdutide’s NDA has been accepted in China. Survodutide expects key Phase 3 readouts in 2025/2026. Within the next 3 years, the obesity medical landscape will be entirely dominated by these synthetic multi-receptor agonists.